These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29272064)

  • 21. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
    Lingvay I; Chao J; Dalal MR; Meneghini LF
    Diabetes Technol Ther; 2017 May; 19(5):315-322. PubMed ID: 28467113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness and safety of different basal insulins in a real-world setting.
    Ji L; Zhang P; Zhu D; Lu J; Guo X; Wu Y; Li X; Ji J; Jia W; Yang W; Zou D; Zhou Z; Gao Y; Garg SK; Pan C; Weng J; Paul SK;
    Diabetes Obes Metab; 2017 Aug; 19(8):1116-1126. PubMed ID: 28230322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective.
    Ponomareva E; Schmerold L; Sss S; Preblick R; Park S; Wilson L; Revel A
    J Med Econ; 2023; 26(1):1469-1478. PubMed ID: 37916295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine.
    Dailey G; Lavernia F
    Diabetes Obes Metab; 2015 Dec; 17(12):1107-14. PubMed ID: 26139151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the clinical effectiveness and safety of insulin glargine 300 U/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real-world evidence study from Saudi Arabia (EVOLUTION).
    Al Malki F; El Damanhoury B; Othman A; Alghamdi Z; AlQahtani M; Madgy A; Chouikrat Z
    Diabetes Obes Metab; 2023 Oct; 25(10):2869-2877. PubMed ID: 37485767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies.
    Wei W; Buysman E; Grabner M; Xie L; Brekke L; Ke X; Chu JW; Levin PA
    Diabetes Obes Metab; 2017 Mar; 19(3):375-386. PubMed ID: 27860158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.
    Yale JF; Aroda VR; Charbonnel B; Sinclair AJ; Trescoli C; Cahn A; Bigot G; Merino-Trigo A; Brulle-Wohlhueter C; Bolli GB; Ritzel R
    Diabetes Metab; 2020 Apr; 46(2):110-118. PubMed ID: 30366067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus.
    Freemantle N; Mauricio D; Giaccari A; Bailey T; Roussel R; Franco D; Berthou B; Pilorget V; Westerbacka J; Bosnyak Z; Bonnemaire M; Cali AMG; Nguyên-Pascal ML; Penfornis A; Perez-Maraver M; Seufert J; Sullivan SD; Wilding J; Wysham C; Davies M
    Curr Med Res Opin; 2020 Apr; 36(4):571-581. PubMed ID: 31865758
    [No Abstract]   [Full Text] [Related]  

  • 31. Early discontinuation and related treatment costs after initiation of Basal insulin in type 2 diabetes patients: a German primary care database analysis.
    Anderten H; Dippel FW; Kostev K
    J Diabetes Sci Technol; 2015 May; 9(3):644-50. PubMed ID: 25573957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.
    Smolen HJ; Murphy DR; Gahn JC; Yu X; Curtis BH
    J Manag Care Spec Pharm; 2014 Sep; 20(9):968-84. PubMed ID: 25166296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3.
    Bonadonna RC; Yale JF; Brulle-Wohlhueter C; Boëlle-Le Corfec E; Choudhary P; Bailey TS
    Diabetes Obes Metab; 2019 Mar; 21(3):715-719. PubMed ID: 30414260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life.
    Oriot P; Jérémie W; Buysschaert M
    Expert Rev Endocrinol Metab; 2018 May; 13(3):167-171. PubMed ID: 30058899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA.
    Mauricio D; Meneghini L; Seufert J; Liao L; Wang H; Tong L; Cali A; Stella P; Carita P; Khunti K
    Diabetes Obes Metab; 2017 Aug; 19(8):1155-1164. PubMed ID: 28251792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety.
    Seufert J; Wiesli P; Fritsche A; Anderten H; Pegelow K; Pscherer S; Pfohl M
    Diabetes Obes Metab; 2022 Jan; 24(1):72-81. PubMed ID: 34514696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
    Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
    Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials.
    Danne T; Matsuhisa M; Sussebach C; Goyeau H; Lauand F; Niemoeller E; Bolli GB
    Diabetes Obes Metab; 2020 Oct; 22(10):1880-1885. PubMed ID: 32515543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.